
Swiss pharma Basilea sheds yet another oncology program as anti-infectives pivot plows forward
Acting on its plans to discard its oncology pipeline, Swiss company Basilea Pharmaceutica has decided to sell its cancer drug BAL0891 to Korean biotech SillaJen for $14 million upfront.
Basilea had announced its decision to ditch its oncology pipeline in February, as a part of a reorganization of its R&D pipeline around anti-infectives, including its two approved drugs in that space. Tuesday’s sale will also fetch Basilea additional milestone payments of up to $320 million and tiered royalties on net sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.